期刊文献+

泊沙康唑干混悬剂的制备及稳定性研究 被引量:2

下载PDF
导出
摘要 目的:制备一种稳定的泊沙康唑干混悬剂,该干混悬剂包括泊沙康唑3.O%-4.0%、填充剂90%-95%、作为润湿剂的表面活性剂0.8%~1.0%。按照本发明制备的干混悬剂,以固体形式储存,方便携带,运输方便,稳定性好。服用前加水适量配制成混悬液,充分摇匀,口服。 The presentinvention relates to a stable dry suspension posaconazple and its preparation method the dry suspension including posaeonazole 3.0%to 4.0% from 90% to 95% filler as awetting agent surfactants 0.8% to 1.0%.Prepared in accordance with the present invention dry suspension stored in solid form easy to carry easy to transport good stability before taking the amount of water formulated into s suspension shake it well orally.
出处 《北方药学》 2014年第8期77-78,共2页 Journal of North Pharmacy
关键词 干混悬剂 粒径分布 Dry suspension Particle size distrbution
  • 相关文献

参考文献3

二级参考文献46

  • 1MUNAYYER HK, MANN PA, CHAU AS, et al. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds [J]. AntimicrobAgents Chemother, 2004,48(10) :3690 -3696.
  • 2PFALLER MA, MESSER SA, BOYKEN L,et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program [ J ]. Diagn Microbiol Infect Dis, 2004, 48 (3) :201 - 205.
  • 3SABATELLI FJ, LEOBENBERG D, MENDRICK A, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against approximately 18, 000 strains of clinically significant yeasts and moulds [ C ]//44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA. Oct 30-Nov 2, 2004.
  • 4PFALLER MA, MESSER SA, BOYKEN L,et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans ( 1990 to 2004) [J]. J Clin Microbiol, 2005,43(9) : 2163 -2167.
  • 5PAPHITOU NI, OSTROSKY-ZEICHNER L, PAETZNICK VL, et al. In vitro antlfungal susceptibilities of Trichosporon species [ J ]. Antimicrob Agents Chemother, 2002,46 ( 6 ) : 1144 - 1146.
  • 6MARCO F, PFALLER MA, MESSER SA,et al. In vitro activity of a new tfiazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi [ J ]. Mycopathologia, 1998,141 ( 1 ) : 73 - 77.
  • 7SUN QN, FOTHERGILL AW, MCCARTHY DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes [ J]. Antimicrob Agents Chemother,2002, 46 (7) : 1581 - 1582.
  • 8GONZALEZ GM, FOTHERGILL AW, SUTTON DA, et al. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi [ J ]. Med Mycol, 2005,43 (2) : 281 -284.
  • 9NUCCI M, AKITI T, BARREIROS G,et al. Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection [J]. J Clin Microbiol, 2001, 39(1): 514 -518.
  • 10PETRAITIENE R, PETRAITIS V, GROLL AH, et al. Antifungal activity and pharmacokinetics of posaconazole( SCH 56592 ) in treatment and prevention of experimental invasive pulmonary aspergillusis : correlation with galactomannan antigenemia [ J ]. Antimicrob Agents Chemother, 2001,45 ( 2 ) :857 - 869.

共引文献8

同被引文献15

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部